Antigen presenting cells, a process for preparing the same and their use as cellular vaccines
AssigneeI.D.M. Immuno-Designed
InventorsMohamed Chokri, Jacques Bartholeyns, Jean-Loup Romet-Lemonne
Life of this patent
Estimating the term…
Abstract
The invention relates to monocytes derived antigen presenting cells (MD-APCs) characterized in that they have the following properties: they present on their surface: antigen CD14 and CD64 with a mean intensity of about 5 to about 200; antigen CD80 and CD86 with a mean intensity of about 20 to about 200; antigen CD40 and mannose receptor with a mean intensity of 50 to 500; they are substantially devoid of the surface antigens CD1a and CD1c; they present a phagocytosis property; and they have the property of stimulating the proliferation of allogenic lymphocytes.
Claims22
A method of preparing monocyte derived antigen presenting cells (MD-APCs), comprising:
- preparing a culture of mononuclear cells in a culture medium comprising a chemical ligand of mononuclear cells,
- allowing said mononuclear cells to differentiate into MD-APCs which present the following properties:
- the presence on the MD-APC cell surface of surface antigens CD80 and CD86, and
- the presence on the MD-APC cell surface of surface antigens CD40 and mannose receptor.
A method of preparing monocyte derived cells (MD-APCs), comprising:
- preparing a culture of mononuculear cells in a culture medium comprising a chemical ligand of mononuclear cells,
- allowing said mononuclear cells to differentiate into MD-APCs which present the following properties:
- a higher phagocytic capacity than mature dendritic cells, and
- a greater capability of stimulating proliferation of allogenic lymphocytes relative to standard macrophages,
A method of preparing a composition comprising monocyte derived cells (MD-APCs), comprising:
- preparing a culture of mononuclear cells in a culture medium comprising a chemical ligand of mononuclear cells,
- allowing said mononuclear cells to differentiate into MD-APCs which present the following properties:
- the presence on the MD-APC cell surface of surface antigens CD80 and CD 86,
- the presence on the MD-APC cell surface of surface antigens CD40 and mannose receptor, and
- the presence on the MD-APC cell surface of surface antigen CD 14.
Dependencies are inferred from the claim text.